Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03748706 · ClinicalTrials.gov registry record · Phase 2
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
A Phase 2 study, sponsored by Pain Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT03748706: Completed Phase 2 study, sponsored by Pain Therapeutics.
NCT03748706 is a Phase 2 study that has completed, run by Pain Therapeutics. The registered enrollment target is 13 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03748706, a Phase 2 study, has completed, sponsored by Pain Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a Phase 2a, multi-center, open-label study of PTI-125 in mild-to-moderate Alzheimer's disease patients.
Primary Outcome
Blood draws will be done to evaluate levels of PTI-125 in the plasma using non-compartmental methods in WinNonlin.
Interventions
- DRUG PTI-125, 100 mg tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-03-07 |
| Est. Completion | 2019-05-08 |
| Phase | Phase 2 |
What the finished NCT03748706 record still lists
NCT03748706 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which PTI-125, 100 mg tablets is the first listed.
NCT03748706 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03748706 about?
NCT03748706 is a clinical study titled "PTI-125 for Mild-to-moderate Alzheimer's Disease Patients". This is a Phase 2a, multi-center, open-label study of PTI-125 in mild-to-moderate Alzheimer's disease patients.
What is the current status of trial NCT03748706?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2019-03-07. Estimated completion is 2019-05-08.
What interventions are being tested in trial NCT03748706?
The interventions under investigation include: PTI-125, 100 mg tablets (DRUG).
Who is sponsoring clinical trial NCT03748706?
This trial is sponsored by Pain Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03748706's enrollment target sits among peer trials
13 1947th of 2000 higher than 53 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI